Tag

GLP-1

19 stories

Deals May 8, 2026

Lilly Drops $4.5B, Opens First Genetic Medicine Plant

Lilly's $4.5B Indiana bet includes the company's first genetic medicine plant and what could become the largest API site in U.S. history.

Deals May 7, 2026

GSK Bought SiranBio for $1B in siRNA Bet

GSK paid up to $1B for SiranBio's Phase 1 siRNA asset targeting ALK7, doubling down on cardiometabolic bets while GLP-1 rivals pile up.

Deals Apr 18, 2026

Raised $625M at $16 a Share, Kailera Tops Moderna's 2018 IPO Record

Kailera Therapeutics priced just under 40 million shares at $16 apiece Friday, pulling in $625 million on its Nasdaq debut under KLRA.

Deals Apr 17, 2026

Kailera Prices $625M IPO, Largest Biotech Since Moderna

Kailera Therapeutics priced its IPO at $625m, or $16 a share, on April 16 — at the top of its S-1 range and one of the largest biotech public offerings…

Deals Apr 17, 2026

Priced at $16, Kailera Raises $625M in Largest Biotech IPO Since 2018

Kailera Therapeutics priced its IPO at $16 a share Friday, raising $625 million, the largest biotech public offering in recent memory, topping Moderna's…

Deals Apr 16, 2026

Cleared $22B: Q1 2026 Obesity Deals Top 2025's Full-Year Total

Biopharma committed $22 billion to obesity and diabetes licensing deals in Q1 2026, clearing last year's full-year total of $20.3 billion with three…

FDA Apr 15, 2026

FDA Cleared Foundayo With 3 Postmarketing Safety Study Requirements

FDA cleared Foundayo, Eli Lilly's oral GLP-1 pill for obesity, on April 1, but the approval letter lists three postmarketing requirements tied to what the…

Deals Apr 13, 2026

Kailera Files $528.5M Nasdaq IPO to Fund Four GLP-1 Obesity Drugs

Kailera filed for a $528.5 million Nasdaq IPO, pricing 33.33 million shares at $14 to $16 each.

FDA Apr 13, 2026

FDA Cleared Foundayo; Lilly Pre-Stocked $1.5B Before Approval

FDA cleared Foundayo eight days ago, and Eli Lilly was ready: the company pre-stocked $1.5 billion worth of the pill back in February, months before…

Deals Apr 10, 2026

Novo Loses GLP-1 Pioneer Lotte Bjerre Knudsen to Retirement

Novo Nordisk is losing a key obesity figure.

FDA Apr 8, 2026

Lilly Foundayo Clears FDA; Novo's Oral Holds 5-Point Lead

Lilly's oral obesity pill approved but trails Novo on weight loss. Pharma's M&A sprint added $7.9B in deals and Trump's tariffs landed with carveouts.

Deals Apr 7, 2026

Lilly Bets on Orexins, Tirzepatide Playbook Repeats

Eli Lilly acquires into the orexin drug class, betting the maturing CNS mechanism follows the same multi-indication arc as GLP-1.

FDA Apr 7, 2026

Novo Nordisk's 7.2 mg Wegovy Hits US Shelves at Triple the Standard Dose

Novo Nordisk's 7.2 mg Wegovy is now available in the US, tripling the standard 2.4 mg dose in a direct bid to reclaim ground lost to Lilly's Zepbound.

Deals Apr 6, 2026

Lilly Pays $7.8B for Centessa to Buy Into the Orexin Race

Lilly is paying $7.8B for Centessa — $38/share plus a $9 CVR — to grab cleminorexton, a Phase IIa orexin agonist for narcolepsy.

deals

Deals Apr 6, 2026

Syneron Bio Closes $150M Series B for Peptides

Syneron Bio raised a $150M Series B for peptide development. GLP-1s proved the format can print billions. The program list is still a mystery.

FDA Apr 5, 2026

Novo Fires Back at Lilly's Foundayo With Competing Efficacy Data

Novo Nordisk published rival efficacy data the day after FDA approved Lilly's oral obesity pill Foundayo — but no head-to-head trial exists to back the claims.

Deals Apr 5, 2026

Lilly Pays $115M Upfront in Insilico AI Deal Worth Up to $2.75B

Eli Lilly paid $115M upfront for an AI collaboration with Insilico Medicine worth up to $2.75B, with milestone math that heavily favors Lilly.

FDA Apr 5, 2026

FDA Clears 7.2mg Wegovy HD for Novo Nordisk in 54-Day Sprint

FDA cleared Novo Nordisk's 7.2mg Wegovy HD in 54 days under its national priority program, pushing the GLP-1's efficacy ceiling higher.

fda

FDA Apr 5, 2026

Lilly's Oral GLP-1 Pill Cleared in 50 Days, Fastest NME Since 2002

Eli Lilly's oral GLP-1 pill orforglipron approved in 50 days under the FDA's CNPV pilot — the fastest new molecular entity approval since 2002.